skip to navigation skip to content
Search

pharmaceuticals

Stock sales

Three US senators cite research by Professor Alan Jagolinzer of Cambridge Judge Business School in urging SEC reform of insider trading laws.  Professor Alan Jagolinzer Three US senators cited research co-authored by Professor Alan Jagolinzer of Cambridge Judge Business School in urging the Securities…

Read more

Woman tracking and trading stocks using laptop and desktop computer. Stock Exchange, investment, and financial trading concept.

Good reporting

Annual reports should inform society – not just shareholders – about vital issues such as the financial health and environmental impact of organisations, says Professor Alan Jagolinzer of Cambridge Judge Business School. Professor Alan Jagolinzer By Professor Alan Jagolinzer Corporate…

Read more

Business people discussing an annual report.

Forbes India: How drug companies can increase their R&D effectiveness

A study co-authored by Professor Stylianos Kavadias and Dr Nektarios Oraiopoulos at University of Cambridge Judge Business School, is featured in the Forbes article. The study demonstrates “how pharmaceutical executives can impact the success of their research and development” programs…

Read more

Call for SEC action

Article co-authored by Professor Alan Jagolinzer of Cambridge Judge calls for Securities and Exchange Commission to reform 'pre-planned' stock sale rules. Professor Alan Jagolinzer An article co-authored by Professor Alan Jagolinzer of Cambridge Judge Business School in The Hill, a…

Read more

Business person using tablet and analysing stock exchange online in monitoring room background, forex trading graph, stock market and financial investment concept.

Cambridge Network: Study examines cultural fit in big pharma integration

Piyush Durani, an Executive MBA graduate of Cambridge Judge (EMBA 2018), measures cultural fit in the $74 billion merger of Bristol-Myers Squibb and Celgene. “As I progressed through my EMBA programme in 2018-2019, the BMS acquisition of Celgene was announced…

Read more

Big pharma

Piyush Durani, an Executive MBA graduate of Cambridge Judge (EMBA 2018), measures cultural fit in the $74 billion merger of Bristol-Myers Squibb and Celgene. Piyush Durani The well-known business expression "culture eats strategy for breakfast" is particularly apt for mergers…

Read more

Cartoon of two business people discussing a pharmaceutical capsule.

Pharma shift

The pharmaceutical industry's focus on procedures and dealmaking could change significantly in this uncertain period, five Cambridge Executive MBA graduates say in a webinar for the What's Next? How to Survive and Thrive in a Post COVID-19 World series. Here's…

Read more

2020 webinars whats next 883x432 1

Investing in Cambridge drug discovery

PharmEnable raises £1.8 million for drug discovery expansion. PharmEnable, a venture supported by the Accelerate Cambridge programme at the Entrepreneurship Centre of Cambridge Judge Business School, said it has secured £1.8 million in a seed financing round led by Cambridge…

Read more

2020 news accelerate pharmenable 883x432 1

Biotech vs big pharma

Most approved "priority" medicines are developed by biotech rather than large pharmaceutical firms, says a two-decade study at the University of Cambridge Judge Business School. Biotech companies created 40 per cent more US Food & Drug Administration-approved "priority" drugs than…

Read more

2020 brainfood oraiopoulos derisking drug innovation 1998x642 1

Manhattan Project?

A "multiple-shots-on-goal" approach is needed to find coronavirus drugs, Cambridge Judge academics say in California Management Review. A many-shots-on-goal approach - not command and control - will most effectively develop vaccines and treatments for COVID-19 (coronavirus), Cambridge Judge Business School academics say in a new California Management Review article. Professor Christoph Loch While some have suggested…

Read more

2020 brainfood manhattan project 883x432 1

Archives